EyeGene Stock

EyeGene FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of EyeGene (185490.KQ) as of Aug 8, 2026 is 45.87 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 141.47 % — a change of -67.58% (lower).

FCF Conversion

45.87 %

YoY

-67.58%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of EyeGene is 2026 45.87 % . FCF Conversion Rate (FCF/EBITDA) of EyeGene was 2025 141.47 % . It decreases by -67.58% lower compared to the previous year.
Access this data via the Eulerpool API

EyeGene Stock analysis

What does EyeGene do? EyeGene Inc is a biotech company focused on the discovery, development, and commercialization of treatment options for rare eye diseases. EyeGene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about EyeGene stock

FCF Conversion Rate (FCF/EBITDA) of EyeGene is 45.87 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of EyeGene changed from 141.47 % to 45.87 %, representing a -67.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) EyeGene since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s EyeGene with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — EyeGene

All Key Metrics — EyeGene